ArticleActa biomaterialia2018
Microgels produced using microfluidic on-chip polymer blending for controlled released of VEGF encoding lentivectors.
Article in Acta biomaterialia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Cardiac Matrix-Derived Granular Hydrogel Enhances Cell Function in 3D Culture.ACS applied materials & interfaces · 2024Article
- The use of hydrogel microspheres as cell and drug delivery carriers for bone, cartilage, and soft tissue regeneration.Biomaterials translational · 2024Review
- 3D printing microporous scaffolds from modular bioinks containing sacrificial, cell-encapsulating microgels.Biomaterials science · 2023Article
- Construction of vascularized tissue-engineered breast with dual angiogenic and adipogenic micro-tissues.Materials today. Bio · 2023Article
- Advanced Microfluidic Technologies for Lipid Nano-Microsystems from Synthesis to Biological Application.Pharmaceutics · 2022Review
- Microvascular Experimentation in the Chick Chorioallantoic Membrane as a Model for Screening Angiogenic Agents including from Gene-Modified Cells.International journal of molecular sciences · 2021Review
- Recent Progress on Polysaccharide-Based Hydrogels for Controlled Delivery of Therapeutic Biomolecules.ACS biomaterials science & engineering · 2021Review
- Droplet Microfluidics for Tumor Drug-Related Studies and Programmable Artificial Cells.Global challenges (Hoboken, NJ) · 2021Review
- Chips for Biomaterials and Biomaterials for Chips: Recent Advances at the Interface between Microfabrication and Biomaterials Research.Advanced healthcare materials · 2021Review
- Polysaccharide-Based Materials Created by Physical Processes: From Preparation to Biomedical Applications.Pharmaceutics · 2021Review
- Microfluidic on-chip production of microgels using combined geometries.Scientific reports · 2021Article
- Biomaterial Based Strategies for Engineering New Lymphatic Vasculature.Advanced healthcare materials · 2020Review
- Computational-Based Design of Hydrogels with Predictable Mesh Properties.ACS biomaterials science & engineering · 2020Article
- A Way to Predict Gold Nanoparticles/Polymer Hybrid Microgel Agglomeration Based on Rheological Studies.Nanomaterials (Basel, Switzerland) · 2019Article
- Recent Advances in Droplet-based Microfluidic Technologies for Biochemistry and Molecular Biology.Micromachines · 2019Review
- Thermoresponsive Poly(Polymers · 2019Article
- Local Structure of CaGels (Basel, Switzerland) · 2019Article
- Application of drug delivery systems for the controlled delivery of growth factors to treat nervous system injury.Organogenesis · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Alginate hydrogels are widely used as delivery vehicles due to their ability to encapsulate and release a wide range of cargos in a gentle and biocompatible manner. The release of encapsulated therapeutic cargos can be promoted or stunted by adjusting the hydrogel physiochemical properties. However, the release from such systems is often skewed towards burst-release or lengthy retention. To address this, we hypothesized that the overall magnitude of burst release could be adjusted by combining microgels with distinct properties and release behavior. Microgel suspensions were generated using a process we have termed on-chip polymer blending to yield composite suspensions of a range of microgel formulations. In this manner, we studied how alginate percentage and degradation relate to the release of lentivectors. Whereas changes in alginate percentage had a minimal impact on lentivector release, microgel degradation led to a 3-fold increase, and near complete release, over 10 days. Furthermore, by controlling the amount of degradable alginate present within microgels the relative rate of release can be adjusted. A degradable formulation of microgels was used to deliver vascular endothelial growth factor (VEGF)-encoding lentivectors in the chick chorioallantoic membrane (CAM) assay and yielded a proangiogenic response in comparison to the same lentivectors delivered in suspension. The utility of blended microgel suspensions may provide an especially appealing platform for the delivery of lentivectors or similarly sized therapeutics. STATEMENT OF SIGNIFICANCE: Genetic therapeutics hold considerable potential for the treatment of diseases and disorders including ischemic cardiovascular diseases. To realize this potential, genetic vectors must be precisely and efficiently delivered to targeted regions of the body. However, conventional methods of delivery do not provide sufficient spatial and temporal control. Here, we demonstrate how alginate microgels provide a basis for developing systems for controlled genetic vector release. We adjust the physiochemical properties of alginate for quicker or slower release, and we demonstrate how combining distinct formulations of microgels can tune the release of the overall composite microgel suspension. These composite suspensions are generated using a straightforward and powerful application of droplet microfluidics which allows for the real-time generation of a composite suspension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.